Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2016 - 2026)
Myriad Genetics has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $12.6 million for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 14.86% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.7 million through Dec 2025, down 12.25% year-over-year, with the annual reading at $53.7 million for FY2025, 12.25% down from the prior year.
- Depreciation & Amortization (CF) was $12.6 million for Q4 2025 at Myriad Genetics, roughly flat from $12.6 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $19.4 million in Q1 2023 and troughed at $12.6 million in Q3 2025.
- The 5-year median for Depreciation & Amortization (CF) is $14.2 million (2021), against an average of $14.6 million.
- Year-over-year, Depreciation & Amortization (CF) tumbled 62.85% in 2021 and then skyrocketed 49.23% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.3 million in 2021, then rose by 3.01% to $13.7 million in 2022, then increased by 10.22% to $15.1 million in 2023, then fell by 1.99% to $14.8 million in 2024, then fell by 14.86% to $12.6 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Depreciation & Amortization (CF) are $12.6 million (Q4 2025), $12.6 million (Q3 2025), and $14.1 million (Q2 2025).